Genezen has made a start on turning its new multiphase master plan for a 75,000-sq. ft cGMP-compliant lentiviral vector production facility into reality.
Genezen Laboratories Inc. has received a majority investment from Ampersand Capital Partners, a private equity firm specializing in growth equity investments in the healthcare sector.